Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer

A phase II trial of celecoxib and docetaxel

Ildiko Csiki, Jason D. Morrow, Alan Sandler, Yu Shyr, John Oates, Myles K. Williams, Thao Dang, David P. Carbone, David H. Johnson

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG) synthesis and is overexpressed in 70% to 90% of non-small cell lung cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clinically, we administared celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m2 every 3 weeks) to a cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor- prostane-1,20-dioic acid (PGE-M), the major metabolite of prostaglandin E 2 (PGE2). We enrolled 56 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11% and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGE-M decreased from a mean level of 27.2 to 12.2 ng/mg Cr after 5 to 10 days of celecoxib (P = 0.001). When grouoed by quartile, patients with the greatest proportional decline in urinary PGE-M levels experienced a longer survival compared to those with no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE2 synthesis in NSCLC seems warranted.

Original languageEnglish (US)
Pages (from-to)6634-6640
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number18
DOIs
StatePublished - Sep 15 2005

Fingerprint

Celecoxib
docetaxel
Cyclooxygenase 2
Non-Small Cell Lung Carcinoma
Survival
Prostaglandins E
Prostaglandins
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer : A phase II trial of celecoxib and docetaxel. / Csiki, Ildiko; Morrow, Jason D.; Sandler, Alan; Shyr, Yu; Oates, John; Williams, Myles K.; Dang, Thao; Carbone, David P.; Johnson, David H.

In: Clinical Cancer Research, Vol. 11, No. 18, 15.09.2005, p. 6634-6640.

Research output: Contribution to journalArticle

Csiki, I, Morrow, JD, Sandler, A, Shyr, Y, Oates, J, Williams, MK, Dang, T, Carbone, DP & Johnson, DH 2005, 'Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel', Clinical Cancer Research, vol. 11, no. 18, pp. 6634-6640. https://doi.org/10.1158/1078-0432.CCR-05-0436
Csiki, Ildiko ; Morrow, Jason D. ; Sandler, Alan ; Shyr, Yu ; Oates, John ; Williams, Myles K. ; Dang, Thao ; Carbone, David P. ; Johnson, David H. / Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer : A phase II trial of celecoxib and docetaxel. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 18. pp. 6634-6640.
@article{a2900853369e463f9e4456ef1a81aec7,
title = "Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel",
abstract = "Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG) synthesis and is overexpressed in 70{\%} to 90{\%} of non-small cell lung cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clinically, we administared celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m2 every 3 weeks) to a cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor- prostane-1,20-dioic acid (PGE-M), the major metabolite of prostaglandin E 2 (PGE2). We enrolled 56 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11{\%} and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGE-M decreased from a mean level of 27.2 to 12.2 ng/mg Cr after 5 to 10 days of celecoxib (P = 0.001). When grouoed by quartile, patients with the greatest proportional decline in urinary PGE-M levels experienced a longer survival compared to those with no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE2 synthesis in NSCLC seems warranted.",
author = "Ildiko Csiki and Morrow, {Jason D.} and Alan Sandler and Yu Shyr and John Oates and Williams, {Myles K.} and Thao Dang and Carbone, {David P.} and Johnson, {David H.}",
year = "2005",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-05-0436",
language = "English (US)",
volume = "11",
pages = "6634--6640",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer

T2 - A phase II trial of celecoxib and docetaxel

AU - Csiki, Ildiko

AU - Morrow, Jason D.

AU - Sandler, Alan

AU - Shyr, Yu

AU - Oates, John

AU - Williams, Myles K.

AU - Dang, Thao

AU - Carbone, David P.

AU - Johnson, David H.

PY - 2005/9/15

Y1 - 2005/9/15

N2 - Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG) synthesis and is overexpressed in 70% to 90% of non-small cell lung cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clinically, we administared celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m2 every 3 weeks) to a cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor- prostane-1,20-dioic acid (PGE-M), the major metabolite of prostaglandin E 2 (PGE2). We enrolled 56 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11% and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGE-M decreased from a mean level of 27.2 to 12.2 ng/mg Cr after 5 to 10 days of celecoxib (P = 0.001). When grouoed by quartile, patients with the greatest proportional decline in urinary PGE-M levels experienced a longer survival compared to those with no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE2 synthesis in NSCLC seems warranted.

AB - Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG) synthesis and is overexpressed in 70% to 90% of non-small cell lung cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clinically, we administared celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m2 every 3 weeks) to a cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11 α-hydroxy-9,15-dioxo-2,3,4,5-tetranor- prostane-1,20-dioic acid (PGE-M), the major metabolite of prostaglandin E 2 (PGE2). We enrolled 56 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11% and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGE-M decreased from a mean level of 27.2 to 12.2 ng/mg Cr after 5 to 10 days of celecoxib (P = 0.001). When grouoed by quartile, patients with the greatest proportional decline in urinary PGE-M levels experienced a longer survival compared to those with no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE2 synthesis in NSCLC seems warranted.

UR - http://www.scopus.com/inward/record.url?scp=25144442153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144442153&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0436

DO - 10.1158/1078-0432.CCR-05-0436

M3 - Article

VL - 11

SP - 6634

EP - 6640

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -